Novavax Initiates Phase 2 Trial of RSV Vaccine; Sees Reporting Top-Line Results in Q1 2013

by Benzinga Staff
October 8, 2012 1:35 PM | 17 seconds read | Make a Comment

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Novavax, Inc. (Nasdaq: NVAX)today announced that enrollment has begun in a Phase 2 dose-ranging clinicaltrial of its respiratory syncytial virus (RSV) vaccine candidate in women ofchildbearing age. The study is being conducted in collaboration with PATH, aninternational nonprofit organization that transforms global health throughinnovation, which is providing approximately $2 million in funding to supportthe trial.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsGuidanceFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.